Escitalopram and suicidality in adult depression and anxiety

International Clinical Psychopharmacology

Volumn 20, Issue 3, 2005, Pages 139-143

  Pedersen, Anders Gersel ^a  

^a H LUNDBECK A S   (Denmark)

Author keywords

Antidepressive agents; Depression; Depressive disorder; Serotonin uptake inhibitors; Suicide

Indexed keywords

CITALOPRAM; ESCITALOPRAM; FLUOXETINE; PAROXETINE; PLACEBO;

ADULT; ANXIETY; ARTICLE; AUTOMUTILATION; COMORBIDITY; DEPRESSION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PRIORITY JOURNAL; RATING SCALE; RELAPSE; SUICIDAL BEHAVIOR; VICTIM;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANXIETY DISORDERS; CITALOPRAM; DATABASES, FACTUAL; DEPRESSIVE DISORDER; HUMANS; PSYCHIATRIC STATUS RATING SCALES; RANDOMIZED CONTROLLED TRIALS; SELF-INJURIOUS BEHAVIOR; SUICIDE;

EID: 17644361929     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-200505000-00003     Document Type: Article

References (24)

1. Angst F, Stassen HH, Clayton PJ, Angst J (2002). Mortality of patients with mood disorders: follow-up over 34-38 years. J Affect Disord 68:167-181.
2. Beasley CM, Bruce ED, Bosomworth JC, Sayler ME, Rampey AH, Heiligenstein JH, Thompson VL, et al. (1991). Fluoxetine and suicide: a meta-analysis of controlled trials of treatment of depression. BMJ 303:685-692.
3. Burke WJ, Gergel I, Bose A (2002). Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 63:331-336.
4. Cheeta S, Schifano F, Oyefeso A, Webb L, Ghodse AH (2004). Antidepressant-related deaths and antidepressant prescriptions in England and Wales, 1998-2000. Br J Psychiatry 184:41-47.
5. Davidson JR, Bose A, Korotzer A, Zheng H (2004). Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study. Depress Anxiety 19:234-240.
6. Goodman WK, Bose A, Wang Q (2003). Escitalopram 10 mg/day is effective in the treatment of GAD. Poster 806 Presented at the 156th Annual Meeting of the American Psychiatric Association, 17-22 May 2003; San Francisco, California.
7. Hall WD, Mant A, Mitchell PB, Rendle VA, Hickie IB, McManus P (2003). Association between antidepressant prescribing and suicide in Australia, 1991-2000: trend analysis. BMJ 326:1008.
8. Isacsson G (2000). Suicide prevention - a medical breakthrough? Acta Psychiatr Scand 102:113-117.
9. Isacsson G, Holmgren P, Ahlner J (2004). Do SSRIs induce suicide? A controlled study of Swedish suicides 1992-2000. Eur Neuropsychopharmacol 14 (suppl 3):S145.
10. Kasper S, Stein DJ, Loft H, Nil R (2005). Escitalopram in the treatment of social anxiety disorder: a randomised, placebo-controlled, flexible-dose study. Br J Psychiatry, in press.
11. Khan A, Khan S, Kolts R, Brown WA (2003). Suicide rates in clinical trials of SSRIs, other antidepressants and placebo: analysis of FDA reports. Am J Psychiatry 160:790-792.
12. Lader M, Stender K, Burger V, Nil R (2004). Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study. Depress Anxiety 19:241-248.
13. Lepola UM, Loft H, Reines EH (2003). Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 18:211-217.
14. Lonnqvist JK, Henriksson MM, Isometsa ET, Marttunen MJ, Heikkinen ME, Aro HM, Kuoppasalmi KI (1995). Mental disorders and suicide prevention. Psychiatry Clin Neurosci 49 (suppl 1):S111-S116.
15. Montgomery SA, Åsberg M (1979). A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382-389.
16. Montgomery S, Cronholm B, Asberg M, Montgomery DB (1978). Differential effects on suicidal ideation of mianserin, maprotiline and amitriptyline. Br J Clin Pharmacol 5:5773-5803.
17. Montgomery SA, Dunner DL, Dunbar GC (1995). Reduction of suicidal thoughts with paroxetine in comparison with reference antidepressants and placebo. Eur Neuropsychopharmacol 5:5-13.
18. Montgomery SA, Dürr-Pal N, Loft H, Nil R (2003). Relapse prevention by escitalopram treatment of patients with social anxiety disorder (SAD). Eur Neuropsychopharmacol 13 (suppl 4):S364.
19. Ninan PT, Ventura D, Wang (2003). Escitalopram is effective and well tolerated in the treatment of severe depression. Poster No. II-22 Presented at the 43rd Annual New Clinical Drug Evaluation Unit Meeting, 27-30 May 2003; Boca Raton, Florida, http://www.nimh.nih.gov/ncdeu/abstracts2003/ncdeu202fm.
20. Rapaport MH, Bose A, Zheng H (2004). Escitalopram continuation treatment prevents relapse of depressive episodes. J Clin Psychiatry 65:44-49.
21. Reines EH, Andersen HF, de Swart H, Kasper S (2004). Tolerability of escitalopram in the treatment of depressed elderly patients. Nord J Psychiatry 58:105.
22. Stahl SM, Gergel I, Li D (2003). Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 64:1322-1327.
23. Storosum JG, van Zwieten BJ, van den Brink W, Gersons BPR, Broekmans AW (2001). Suicide risk in placebo-controlled studies of major depression. Am J Psychiatry 158:1271-1275.
24. Wade A, Lemming MO, Hedegaard KB (2002). Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 17:95-102.